Surprise, surprise, MCET funding another project to cure ANOTHER deadly incurable disease. Who would have thunk it!
Therapeutic product developer to fund research into antiapoptosis compound
Released : Dec 26, 2005 7:02 AM
2005 DEC 26 - (NewsRx.com) -- MultiCell Technologies, Inc. (MCET) announced that it has entered into a research agreement to investigate a novel antiapoptosis compound to determine whether the compound can protect against retinal ganglion cell (RGC) death in acute and chronic in vivo models of optic neuropathy.
MultiCell will fund research at Columbia University Medical Center, and will have an option to enter into an exclusive worldwide license for any invention resulting from the research.
The underlying mechanisms of RGC death are not fully understood, though RGC apoptosis has been heavily implicated in many ocular neurodegenerative diseases. Given the delicate balance between the survival and death signals in neuronal cells, molecules that are capable of inhibiting apoptosis are strongly considered as future therapeutic options for the treatment of ocular neurodegenerative diseases. James C. Tsai, associate professor of ophthalmology, at Columbia University College of Physicians & Surgeons, will direct the research program.
MultiCell Technologies, Inc. is a developer of therapeutic products, and a supplier of immortalized human cell lines for drug discovery applications.
Columbia University Medical Center focuses on preclinical and clinical research, in medical and health sciences education, and in patient care.
This article was prepared by Pain & Central Nervous System Week editors from staff and other reports. Copyright 2005, Pain & Central Nervous System Week via NewsRx.com.
Copyright 2005 Pain & Central Nervous System Week via NewsRx.com |
